Seeing What Standard Tests Miss
New research demonstrates that optical genome mapping (OGM) can detect clinically significant genetic variants that conventional diagnostic methods miss in nearly one out of every five patients with acute leukemia. The findings, which could alter treatment decisions for a substantial fraction of leukemia patients, add to growing evidence that OGM technology is ready to complement or replace some traditional cytogenetic testing methods in clinical oncology.
Acute leukemia — which includes acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) — is driven by genetic mutations that cause blood cell precursors to multiply uncontrollably. Identifying the specific mutations present in a patient's leukemia is critical for treatment planning, as different genetic subtypes respond to different therapies.
How Optical Genome Mapping Works
Traditional cytogenetic methods for detecting genetic abnormalities in leukemia include karyotyping — visually examining chromosomes under a microscope — and fluorescence in situ hybridization (FISH), which uses fluorescent probes to detect specific chromosomal regions. These methods have been standard practice for decades but have significant limitations.
Karyotyping requires cells to be cultured and dividing, which fails in a significant fraction of leukemia samples. FISH can only detect the specific genetic targets it is designed to probe. Both methods have limited resolution for detecting smaller structural variants.
Optical genome mapping takes a fundamentally different approach. Instead of examining individual cells, OGM extracts ultra-long DNA molecules from patient samples, labels them with fluorescent tags at specific sequence motifs, and passes them through nanochannels where high-resolution cameras image the fluorescent pattern. Software then assembles these individual molecule images into a genome-wide map, comparing it against a reference genome to identify structural variants.
The key advantage is the ability to detect structural variants across the entire genome in a single assay, without the need for cell culture or prior knowledge of which variants to look for.
The Study's Findings
The research assessed OGM's diagnostic performance in a cohort of patients with acute leukemia who had already undergone standard cytogenetic testing. OGM confirmed all previously identified clinically significant variants. But critically, in nearly 20 percent of cases, OGM identified additional genetic variants that had not been detected by standard karyotyping and FISH.
These additional variants included cryptic chromosomal rearrangements — structural changes too small or too complex to be resolved by conventional cytogenetics — as well as novel fusion genes and deletions affecting known cancer-related genes.
Several of these newly detected variants had direct clinical implications. Some placed patients into different risk categories, potentially changing whether they would be recommended for intensive chemotherapy, targeted therapy, or stem cell transplantation. Others identified therapeutic targets that could be addressed with drugs already approved or in clinical trials.
Clinical Implications
If one in five leukemia patients carries clinically significant mutations that conventional testing misses, the implications for treatment planning are substantial. Patients currently classified as standard-risk based on conventional cytogenetics may actually carry high-risk genetic features detectable only by OGM, meaning they could benefit from more aggressive initial therapy. Conversely, patients currently receiving intensive treatment might be eligible for less toxic targeted therapies if OGM reveals their full mutational landscape.
The technology also has potential value in monitoring treatment response. By performing OGM at diagnosis and at key treatment milestones, clinicians could track whether specific genetic clones are being eliminated by therapy or persisting and potentially driving relapse.
Adoption and Cost Considerations
Despite its diagnostic advantages, OGM faces practical barriers to widespread clinical adoption. The technology requires specialized laboratory equipment, trained personnel, and bioinformatics infrastructure. Turnaround times, while improving, are currently longer than some conventional methods.
Cost is another consideration. While OGM can replace multiple conventional assays — karyotyping, FISH, and chromosomal microarray — with a single test, the per-assay cost is currently higher than individual conventional methods. Health systems will need to evaluate whether the clinical benefit of detecting additional variants in 20 percent of patients justifies the additional cost.
Several large academic medical centers have already begun incorporating OGM into their diagnostic workflows for hematologic malignancies, and clinical laboratory guidelines are being updated to include OGM alongside conventional methods. As the technology matures, costs decrease, and clinical evidence accumulates, OGM is likely to transition from a supplementary research tool to a standard component of leukemia diagnosis.
For the nearly 20 percent of leukemia patients whose critical mutations are currently invisible to standard testing, that transition cannot come soon enough.
This article is based on reporting by Medical Xpress. Read the original article.
